Back to results
US 10,441,585 B2Granted
Formulations containing nalbuphine and uses thereof
AssigneeDebregeas Et Associes Pharma
InventorsChristophe Lebon, Pascal Suplie, David Olivier Paul
Life of this patent
Estimating the term…
Abstract
Immediate release, oral, pharmaceutical formulation comprising nalbuphine or a pharmaceutically acceptable salt thereof, and at least one hydrophilic granulation carrier, one hydrophilic binder and one lubricant.
Claims10
An immediate release, oral pharmaceutical formulation comprising in percentage by weight:
- 20.55% nalbuphine/HCl,
- 22.02% lactose,
- 47.53% microcrystalline cellulose,
- 4.98% povidone,
- 0.50% magnesium stearate,
- 3.98% flavoring, and
- 0.44% coating.
4 more elements
An immediate release, oral pharmaceutical formulation comprising in percentage by weight:
- 20.31% nalbuphine/HCl,
- 62.16% agglomerated α-lactose-monohydrate,
- 6.65% povidone,
- 2.38% crospovidone,
- 1.76% microcrystalline cellulose,
- 0.10% silica,
- 0.48% magnesium stearate,
- 1.92% talc, and
- 4.81% coating.
6 more elements
Dependencies are inferred from the claim text.